<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415658</url>
  </required_header>
  <id_info>
    <org_study_id>ODRC-002</org_study_id>
    <nct_id>NCT04415658</nct_id>
  </id_info>
  <brief_title>Intravenous Thyroxine for Heart-Eligible Organ Donors</brief_title>
  <official_title>A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mid-America Transplant</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will evaluate whether intravenous thyroxine infusion given&#xD;
      to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more&#xD;
      hearts transplanted than saline placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Brain death frequently induces hemodynamic instability and cardiac stunning.&#xD;
      Impairments in cardiac performance are major contributors to hearts from otherwise eligible&#xD;
      organ donors not being transplanted. Deficiencies in pituitary hormones (including thyroid&#xD;
      stimulating hormone) may contribute to hemodynamic instability and replacement of thyroid&#xD;
      hormone has been proposed as a means of improving stability and increasing hearts available&#xD;
      for transplantation. Intravenous thyroxine is commonly used in donor management. However,&#xD;
      small controlled trials have not been able to demonstrate efficacy.&#xD;
&#xD;
      Methods: This multicenter study will involve organ procurement organizations (OPOs) across&#xD;
      the country. A total of 800 heart-eligible brain dead organ donors who require vasopressor&#xD;
      support will be randomly assigned to intravenous thyroxine for at least 12-hours or saline&#xD;
      placebo. The primary study hypothesis is that thyroxine treatment results in more hearts&#xD;
      transplanted. Additional outcome measures are time to achieve hemodynamic stability (weaning&#xD;
      off vasopressors) and improvement in cardiac ejection fraction on echocardiography.&#xD;
&#xD;
      Discussion: This will be the largest randomized controlled study to evaluate the efficacy of&#xD;
      thyroid hormone treatment for organ donor management. By collaborating across multiple OPOs,&#xD;
      it will be able to enroll an adequate number of donors and be powered to definitively answer&#xD;
      the critical question of whether treatment increases hearts transplanted and/or provides&#xD;
      other hemodynamic benefits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart transplanted</measure>
    <time_frame>One week</time_frame>
    <description>Whether heart is transplanted into living recipient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft function</measure>
    <time_frame>30 days</time_frame>
    <description>30-day graft survival of hearts transplanted from study donors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time till off vasopressors</measure>
    <time_frame>72 hours</time_frame>
    <description>Time in hours from randomization to when weaned off vasopressors (except vasopressin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaned off vasopressors</measure>
    <time_frame>12 hours</time_frame>
    <description>Weaned off vasopressors within twelve hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to order echo</measure>
    <time_frame>72 hours</time_frame>
    <description>Time till hemodynamic stability permits ordering initial echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>72 hours</time_frame>
    <description>Left ventricular ejection fraction measured on first echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total organs transplanted</measure>
    <time_frame>One week</time_frame>
    <description>Total number of organs transplanted</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Brain Death</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Thyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous thyroxine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyroxine</intervention_name>
    <description>Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.</description>
    <arm_group_label>Thyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Declared dead by neurologic criteria (brain dead)&#xD;
&#xD;
          -  Authorization for organ donation and research&#xD;
&#xD;
          -  On one or more vasopressors and/or inotropes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain death declared more than 24 hours prior&#xD;
&#xD;
          -  Only vasopressor is vasopressin&#xD;
&#xD;
          -  Weight &lt; 45 kg (100 lbs)&#xD;
&#xD;
          -  Known coronary artery disease or history of myocardial infarction&#xD;
&#xD;
          -  Known valvular heart disease&#xD;
&#xD;
          -  Prior sternotomy or cardiac surgery&#xD;
&#xD;
          -  Donor at VA hospital&#xD;
&#xD;
          -  Received intravenous or oral thyroxine within past month&#xD;
&#xD;
          -  Known HIV+ status&#xD;
&#xD;
          -  Other reason donor is unable to receive study drug (determined by on-site personnel)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajat Dhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Marklin, MD</last_name>
    <phone>314-735-8291</phone>
    <email>gmarklin@midamericatransplant.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Coby O'Sullivan</last_name>
    <phone>3147358200</phone>
    <email>cosullivan@midamericatransplant.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Donor Network of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PJ Geraghty</last_name>
      <phone>602-222-2482</phone>
      <email>PJ@dnaz.org</email>
    </contact>
    <contact_backup>
      <last_name>Kayla Grey, CCRP</last_name>
      <phone>602 222-2258</phone>
      <email>kayla.gray@dnaz.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lifesharing</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Trageser, MSN, RN</last_name>
      <phone>619-543-4961</phone>
      <email>jtrageser@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jaclyn Russe</last_name>
      <email>jrusse@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Donor Alliance</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Ruterbories, CPTC, CTBS</last_name>
      <phone>303-329-4747</phone>
      <email>jruterbories@donoralliance.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OurLegacy</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Huckestein</last_name>
      <email>Laura.Huckestein@OurLegacyFL.org</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Staman</last_name>
      <email>tiffany.staman@ourlegacyfl.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Iowa Donor Network</name>
      <address>
        <city>North Liberty</city>
        <state>Iowa</state>
        <zip>52317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Stephenson, RN, MSN</last_name>
      <email>mstephenson@iadn.org</email>
    </contact>
    <contact_backup>
      <last_name>Briann Davis</last_name>
      <email>bdavis@iadn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Midwest Transplant Network</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ott</last_name>
      <email>mott@mwtn.org</email>
    </contact>
    <contact_backup>
      <last_name>Scott Sander</last_name>
      <phone>913-261-7303</phone>
      <email>ssander@mwtn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Louisiana Organ Procurement Agency</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joey Boudreaux</last_name>
      <phone>504-837-3355</phone>
      <phone_ext>288</phone_ext>
      <email>jboudreaux@lopa.org</email>
    </contact>
    <contact_backup>
      <last_name>Tina Madere</last_name>
      <phone>504 606-0689</phone>
      <email>tmadere@lopa.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mid-America Transplant Services</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Marklin, MD</last_name>
      <phone>314-735-8291</phone>
      <email>gmarklin@midamericatransplant.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lifebanc</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Goss</last_name>
      <phone>216-408-6092</phone>
      <email>KimberlyG@lifebanc.org</email>
    </contact>
    <contact_backup>
      <last_name>Dan Lebovitz, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LifeShare of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Southwest Transplant Alliance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Forquer</last_name>
      <phone>214-522-0255</phone>
      <email>sforquer@organ.org</email>
    </contact>
    <contact_backup>
      <last_name>Erin Vines</last_name>
      <email>evines@organ.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Organ Sharing Alliance</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Dworaczyk</last_name>
      <phone>210-614-7030</phone>
      <email>sdworaczyk@tosa1.org</email>
    </contact>
    <contact_backup>
      <last_name>Micah Williams</last_name>
      <phone>512-757-6011</phone>
      <email>MWilliams@tosa1.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>DonorConnect</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>LifeCenter Northwest</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dhar R, Stahlschmidt E, Yan Y, Marklin G. A randomized trial comparing triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable brain-dead organ donors. Clin Transplant. 2019 Mar;33(3):e13486. doi: 10.1111/ctr.13486. Epub 2019 Feb 12.</citation>
    <PMID>30689222</PMID>
  </reference>
  <reference>
    <citation>Dhar R, Stahlschmidt E, Marklin G. A Randomized Trial of Intravenous Thyroxine for Brain-Dead Organ Donors With Impaired Cardiac Function. Prog Transplant. 2020 Mar;30(1):48-55. doi: 10.1177/1526924819893295. Epub 2019 Dec 5.</citation>
    <PMID>31802716</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rajat Dhar</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Organ donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Appendix (Data Forms)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04415658/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Main Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04415658/Prot_004.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

